公开(公告)号：US11993661B2

公开(公告)日：2024-05-28

申请号：US17253589

申请日：2019-06-17

申请人： EUREKA THERAPEUTICS, INC.

发明人： Hong Liu ,  Hongruo Yun ,  Xiaomei Ge ,  Zhiyuan Yang ,  Lianxing Liu ,  Pengbo Zhang ,  Yixiang Xu ,  Shan Li ,  Lucas Horan

IPC分类号： C07K16/00 ,  A61P35/00 ,  C07H21/04 ,  C07K14/705 ,  C07K14/725 ,  C07K16/28 ,  C07K16/30 ,  C07K16/46 ,  C12N5/02 ,  C12N15/00 ,  G01N33/574

CPC分类号： C07K16/3069 ,  A61P35/00 ,  C07K14/7051 ,  C07K14/70521 ,  C07K16/2809 ,  G01N33/57434 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/622 ,  C07K2319/02 ,  C07K2319/03

摘要： The present application provides constructs comprising an antibody moiety that specifically binds to PSMA (e.g., PSMA expressed on the surface of a cell). Also provided are methods of making and using these constructs.

公开(公告)号：US11827672B2

公开(公告)日：2023-11-28

申请号：US17043352

申请日：2019-03-29

申请人： Eureka Therapeutics, Inc.

发明人： Jun Cui ,  Pengbo Zhang ,  Yiyang Xu ,  Shan Li ,  Yixiang Xu ,  Guangyan Xiong ,  Hongruo Yun ,  Lianxing Liu ,  Xiaomei Ge ,  Shaohua Xu ,  Hong Liu ,  Javier Morales

IPC分类号： C07K16/28 ,  A61P35/00 ,  C07K14/725 ,  A61K39/00 ,  G01N33/574

CPC分类号： C07K16/2803 ,  A61P35/00 ,  C07K14/7051 ,  C07K16/2809 ,  G01N33/57492 ,  A61K2039/505 ,  C07K2317/31 ,  C07K2317/622 ,  C07K2319/02 ,  C07K2319/03 ,  G01N2333/70503

摘要： Described herein are antibodies (e.g., single chain variable fragment (scFv) antibodies) and constructs comprising antibody moieties that bind to the extracellular domain of CD22 or a portion thereof (e.g., SEQ ID NO: 205 or a portion thereof). Also provided herein are methods of using the same or compositions thereof for the therapeutic treatment of diseases characterized by CD22 expression, in particular, B-cell lymphomas and leukemias.

公开(公告)号：US20220323497A1

公开(公告)日：2022-10-13

申请号：US17628120

申请日：2020-07-24

申请人： Eureka Therapeutics, Inc.

发明人： Hongruo YUN ,  Jun Cui ,  Pengbo Zhang ,  Yiyang Xu ,  Lucas Horan ,  Shaohua Xu ,  Guangyan Xiong ,  Shan Li ,  Yixiang Xu ,  Bradley Austin Heller ,  Hongbing Zhang ,  Hong Liu

IPC分类号： A61K35/17 ,  C12N5/0783 ,  C12N15/62 ,  C12N15/86 ,  C07K14/725 ,  C07K14/705 ,  A61P35/00

摘要： Described herein are immune cells comprising: a chimeric antigen receptor (CAR) that comprises (i) an extracellular target-binding domain comprising an antibody moiety; (ii) a transmembrane domain; and (iii) a primary signaling domain, and a chimeric stimulating receptor (CSR) that comprises (i) a ligand-binding module that is capable of binding or interacting with a target ligand; (ii) a transmembrane domain; and (iii) a CD30 costimulatory domain, in which the CSR in the immune cells lacks a functional primary signaling domain. Also provided herein are methods of using the same or compositions thereof for therapeutic treatment of cancers (e.g., hematological cancers or solid tumor cancers).

公开(公告)号：US20210017280A1

公开(公告)日：2021-01-21

申请号：US17043352

申请日：2019-03-29

申请人： Eureka Therapeutics, Inc.

发明人： Jun CUI ,  Pengbo Zhang ,  Yiyang Xu ,  Shan Li ,  Yixiang Xu ,  Guangyan Xiong ,  Hongruo Yun ,  Lianxing Liu ,  Xiaomei Ge ,  Shaohua Xu ,  Hong Liu ,  Javier Morales

IPC分类号： C07K16/28 ,  C07K14/725 ,  G01N33/574 ,  A61P35/00

摘要： Described herein are antibodies (e.g., single chain variable fragment (scFv) antibodies) and constructs comprising antibody moieties that bind to the extracellular domain of CD22 or a portion thereof (e.g., SEQ ID NO: 205 or a portion thereof). Also provided herein are methods of using the same or compositions thereof for the therapeutic treatment of diseases characterized by CD22 expression, in particular, B-cell lymphomas and leukemias.